Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation

Liver Transplantation

Volumn 21, Issue 2, 2015, Pages 187-194

  Vagefi, Parsia A ^a   Dodge, Jennifer L ^b   Yao, Francis Y ^b   Roberts, John P ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE; OBSERVATIONAL METHOD; ORGAN DONOR; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT OUTCOME; TUMOR VOLUME; UNIVARIATE ANALYSIS; AGED; CARCINOMA, HEPATOCELLULAR; DONOR; FACTUAL DATABASE; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; REGISTER; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TUMOR RECURRENCE; UNITED STATES;

AGED; CARCINOMA, HEPATOCELLULAR; DATABASES, FACTUAL; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; REGISTRIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TISSUE DONORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84921764295     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24042     Document Type: Article

References (19)

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;11:693-699.
2. Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 2011;11:2362-2371.
3. Samoylova ML, Dodge JL, Vittinghoff E, Yao FY, Roberts JP. Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database. Liver Transpl 2013;19:1318-1323.
4. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008;143:182-188.
5. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10 534-540.
6. Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. Dig Dis Sci 2012;57:806-812.
7. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783-790.
8. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008;134:1342-1351.
9. Washburn K, Edwards E, Harper A, Freeman R. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010;10:1643-1648.
10. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
11. van der Bilt JD, Kranenburg O, Nijkamp MW, Smakman N, Veenendaal LM, Te Velde EA, et al. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 2005;42:165-175.
12. van der Bilt JD, Kranenburg O, Borren A, van Hillegersberg R, Borel Rinkes IH. Ageing and hepatic steatosis exacerbate ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Ann Surg Oncol 2008;15:1392-1398.
13. Lai JC, Roberts JP, Vittinghoff E, Terrault NA, Feng S. Patient, center and geographic characteristics of nationally placed livers. Am J Transplant 2012;12:947-953.
14. Croome KP, Wall W, Chandok N, Beck G, Marotta P, Hernandez-Alejandro R. Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl 2013;19:1214-1223.
15. Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
16. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252.
17. Flemming JA, Vagefi PA, Freise CE, Yao FY, Terrault NA, Restricting liver transplant recipients to younger donors does not increase the wait-list time or the drop-out rate: the hepatitis C experience. Liver Transpl 2014;20:1202-1210.
18. Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl 2010;16:925-929.
19. Samoylova ML, Dodge JL, Yao FY, Roberts JP. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2014;20:937-944.